The Florida Senate

COMMITTEE MEETING EXPANDED AGENDA

BANKING AND INSURANCE Senator Broxson, Chair Senator Rouson, Vice Chair

	TIME:	Tuesday, November 5, 2019 2:00—4:00 p.m. <i>Pat Thomas Committee Room,</i> 412 Knott Building			
	MEMBERS:	Senator Broxso Taddeo, and Tl	on, Chair; Senator Rouson, Vice Chair; Senators hurston	Brandes, Gruters, Lee, Perry,	
TAB	BILL NO. and INTR	ODUCER	BILL DESCRIPTION and SENATE COMMITTEE ACTIONS	COMMITTEE ACTION	

Presentations on the role of Pharmacy Benefit Managers in the Private Insurance Market Presented

Other Related Meeting Documents

Shane Abbott, Pharm.D. Co-Owner, The Prescription Place in Defuniak Springs, FL

Shane Abbott is the co-owner of The Prescription Place, a locally owned, independent pharmacy in Defuniak Springs, FL. Upon graduation, Shane returned home to DeFuniak Springs, Florida to practice and provide care for family, friends and his community. In 2006 he and another local pharmacist opened and still co-own The Prescription Place.

Shane is a graduate of the University of Florida College of Pharmacy.

Senate Banking & Insurance Committee Tuesday, November 5, 2019

Presenter: Shane Abbott The Prescription Place



15% Decrease in # of Independent Pharmacies in FL





Source: Quest Analytics analysis of NCPDP Pharmacy Count Data, 2019

Decrease leads to...



Patients lose their local pharmacy



Patients have to drive out of their way to get their prescriptions



Often leads to an overall drop in medication adherence

Problem stems from...





Contracting Issues





Arbitrary Payments



Debilitating Clawbacks

Contracting



PSAOs are presented with take it or leave it contracts Plan sends pharmacy direct contract that is take it or leave it

Non-negotiable contracts as a result of monopolies Closed networks cause patient access issues and eliminate competition

Inefficient contract processes leave neighborhood pharmacies struggling to provide services for their patients

Payments

- Maximum Allowable Costs (MAC)
 - Same PBM uses several MACs
 - PBMs uses MAC to adjust profit margin to benefit themselves, not the patient
 - Currently subsidizing Medicaid



Steering





- PBMs use letters, phone calls, and other incentives to convince patients to use their own pharmacy or mail order pharmacy
- Specialty drugs are required to be filled at their pharmacy only
- Frequently, this steering leads to patient compliance issues due to non-local access

Clawbacks



- Independent pharmacies live in fear of fraudulent audits
- Independent pharmacies receive payments that are less than at the time of adjudication
 - In network fees
 - Out of network fees
 - Customer service fees
- Clawback money is being used to improve profit margins and not lower health care costs

Independent pharmacies <u>lose</u> money providing patients with necessary prescriptions

Focus On:



Most crucial factor that needs to be addressed is the reduced access for patients.

This can be accomplished through...

- No narrow networks for Medicaid
- No payment below cost of drug
- No steerage for PBM-owned pharmacies, mail order or specialty

- No POST adjudication fees
- No abusive audits with drug cost recoupment (other than fraud)

Contact

Shane Abbott

Prescription Place 1337 US Hwy 90 W DeFuniak Springs, FL 32433 850-892-6898 prescriptionplace@yahoo.com



Small Business Pharmacies Aligned for Reform

Tom Brownlie, M.S. Senior Director, U.S. Policy, Pfizer Global Policy

Tom brings over 15 years of experience in various facets of the biopharmaceutical industry. Tom leads Pfizer's U.S. State Policy team and is responsible for developing and implementing coordinated national strategies to ensure Pfizer's policy strategies are patient-centered and align with enterprise-wide objectives. Tom's health policy expertise includes insurance benefit design, utilization management, drug pricing, the drug supply chain, prescription drug importation, health information technology (HIT), prescription drug abuse, Medicaid, Affordable Care Act implementation, and conflict of interest. Tom holds a Bachelor of Science in biology and nutrition, and a Master of Science in nutritional sciences, with minors in epidemiology and international nutrition, from Cornell University.

Pharmaceutical Supply Chain: Patient Impact

November 5, 2019



Pharmaceutical Supply Chain



Breakthroughs that change patients' lives

Source: Adapted from Drug Channels, February 3, 2016. Available at https://www.drugchannels.net/2016/02/follow-dollar-us-pharmacy-distribution.html.

Role of PBMs



Breakthroughs that change patients' lives

Source: PCMA Presentation, Oklahoma Chamber of Commerce Health Summit. Oct. 10, 2018.

List vs. Negotiated Price Growth



Breakthroughs that change patients' lives

Source: Drug Channels, "Drug Prices Are NOT Skyrocketing – They're Barely Growing at All." January 2019. https://www.drugchannels.net/2019/01/drug-prices-are-not-skyrocketingtheyre.html

Spending Trend



Breakthroughs that change patients' lives

Sources: Express Scripts, "Prescription drug pricing: A public policy analysis." February 2019. CVS Health, "2018 Drug Trend Report," April 2019. https://payorsolutions.cvshealth.com/insights/2018-drug-trend-report.

Patient Cost-Sharing Trends



Breakthroughs that change patients' lives

Sources: Avalere Health, *Plans with More Restrictive Networks Comprise 73% of the Exchange Market.* November 2017. Available at: http://avalere.com/expertise/managed-care/insights/plans-with-more-restrictive-networks-comprise-73-of-exchange-market. "2018 Employer Health Benefits Survey," Kaiser Family Foundation. September 2017. Available at: http://files.kff.org/attachment/Report-Employer-Health-Benefits-Annual-Survey-2018.

Impact on Patients



Breakthroughs that change patients' lives

Source: Adapted from Milliman White Paper, "A primer on prescription drug rebates: Insights into why rebates are a target for reducing prices. May 2018.

Impact on Patients



Breakthroughs that change patients' lives

Thank you!





Tricia Fitzsimmons Director of Public Policy, Novartis

Tricia Fitzsimmons is the Director of Public Policy for Novartis focused on pricing policy and strategy. In her role, Tricia is responsible for developing policy positions and working with all U.S. Novartis businesses to assess the impact of federal and state legislative and administrative pricing proposals in the US healthcare system. Her prior pharmaceutical and biopharmaceutical industry experience includes commercial, managed care, and government pricing and contracting roles at Sandoz (a subsidiary of Novartis), Bayer Pharmaceuticals, and GE Healthcare Life Sciences.

Tricia has her Bachelor's Degree in Political Science and Government/Law and her Juris Doctor with a concentration in Healthcare and Pharmaceutical law from the Center for Health Law & Policy, Seton Hall University School of Law.

Jacqueline Jacobi Regional Director of Pharmacy for Florida, New York and South Carolina, Molina Healthcare of Florida

Jacqueline Jacobi's passion for Pharmacy can be traced back to her first job working for an independent Pharmacy where she first experienced the true impact a Pharmacist could really make. Currently working as Regional Director of Pharmacy for Molina of Florida, New York and South Carolina is widely known for her strengths in Pharmacy Operations and her clinical expertise. Based in NY, Jackie, also does volunteering for Non for profit organizations and precepting for Pharmacy students in 2 of NY's Pharmacy schools.

Molina Healthcare of Florida Jacqueline Jacobi, RPH Regional Director of Pharmacy for Florida, New York and South Carolina



Molina Healthcare of Florida

- Molina Healthcare of Florida provides government-funded care for low-income individuals. Our mission is to provide quality health care to people receiving government assistance.
- We serve approximately 140,000 members through Medicaid, Medicare, and Health Insurance Marketplace programs.





Molina Healthcare of Florida

ALTHCARE

Typical Services that PBMs Perform for MCOs



How a MCO Selects a PBM: the RFP Process

PLAN ISSUES RFP

RFP dictates the terms and conditions of the PBM services that the client wants the PBM to perform and the way it wants to reimburse the PBM for the services it offers.

PBM BIDS

Clients typically use benefit consultants who send the RPFs to multiple PBMs the environment is highly competitive.

CLIENT DECISION

Client makes decisions based upon its needs and how it wants to structure its pharmacy benefit.

PLAN DESIGN

Client makes the final decision about the drug benefit plan. PBM provides options based on client's unique needs, but client makes all the decisions.











Complex Market Dynamics Create Challenges for Pharmacy and Whole Health Management



\$45B

per year could be saved through better care coordination³



Proven Value of PBMs in Medicare Part D

The Government Accountability Office (GAO) released a PBM report¹ in July 2019 on how Part D plans are utilizing PBMs to gain value:

- Plans rely on PBMs. Part D plans used PBMs to provide 74% of drug benefit management services.
 - Drug benefit management services include: negotiating rebates, establishing pharmacy networks, formulary development, management of a Pharmacy & Therapeutics Committee, utilization management (a process to ensure that drug use is based on medical necessity, efficiency, and appropriateness), claims adjudication, enrollment processing, enrollee appeals and grievance process management, customer service, coordination with other drug benefit programs, and pharmacy technical assistance.
- PBMs pass through rebates. PBMs negotiated approximately \$18 billion in rebates from drug makers for Part D plans and passed through 99.6% of those dollars.
- Rebates are used by plans to lower premiums. This is why Part D premiums have remained flat.
 - Premiums were relatively unchanged between 2010-2015, even though total gross Part D drug costs grew 12% in that same period.
- The amount of rebates and other price concessions is growing rapidly. From 2014 to 2016, rebates and other price concessions increased from \$17.5 billion to \$29 billion a 66% increase showing the value PBMs provide in lowering costs.



Developing the Formulary

	Florida	New York	South Carolina
Medicaid	AHCA sets the formulary, the criteria	Molina sets the formulary, the criteria and gets all rebates	Molina sets the formulary, the criteria and gets all rebates,
Wiedicald	and gets all rebates.	except HIV, which are accounted for in rates.	which are accounted for in rates.
Marketplace	Molina sets the formulary, the criteria and gets all of the rebates to help reduce premiums.	Molina sets the formulary, the criteria and gets all of the rebates which are applied to reducing the premiums	Molina sets the formulary, the criteria and gets all of the rebates which are applied to reducing the premiums
Medicare	Molina selects one of the formularies that is provided by the PBM	N/A	N/A



One Driver of Cost Increase in Pharmaceutical Spend

2010 ¹				
Rank	Drug	Worldwide Sales		
1	Lipitor	\$10.7B		
2	Plavix	\$9.4B		
3	Advair	\$8.3B		
4	Enbrel**	\$7.3B		
5	Humira**	\$6.5B		
6	Zyprexa	\$5.0B		
7	Nexium	\$5.0B		
8	Singulair	\$5.0B		
9	Seroquel	\$5.0B		
10	Lovenox	\$3.6B		
Total Top 10		\$65.8 B		

	2018 ²	
Rank	Drug	Worldwide Sales
1	Humira**	\$19.9B
2	Eliquis	\$9.9B
3	Revlimid	\$9.7B
4	Opdivo	\$7.6B
5	Keytruda	\$7.2B
6	Enbrel**	\$7.1B
7	Herceptin	\$7.0B
8	Avastin	\$6.8B
9	Rituxan	\$6.7B
10	Xarelto	\$6.6B
Total Top	10	\$88.5 B

Pharma's TV advertising spend increased about 8% in 2018 to \$3.73B¹

	Rank	Drug Name	Use	TV Ad Spend	% of Spend
	1	Humira	inflammatory conditions	\$375M	10.0%
	2	Lyrica	neuropathic pain	\$213M	5.7%
	3	Xeljanz	inflammatory conditions	\$209M	5.6%
	4	Trulicity	diabetes	\$183M	4.9%
	5	Xarelto	prevent blood clots/stroke	\$143M	3.8%
	6	Otezla	inflammatory conditions	\$139M	3.7%
	7	Eliquis	prevent blood clots/stroke	\$136M	3.6%
	8	Keytruda	oncology	\$107M	2.9%
	9	Ibrance	oncology	\$92M	2.5%
	10	Jardiance	diabetes	\$86M	2.3%



Policy Areas which Can Cause Member Disruption and Pharmacy Hardships:

- **Transitional fills** State PDL conflicts with continuity of care. If we comply with the PDL and use a name brand, we increase costs. If we keep the original, we get audited.
- **Immediacy of Fills** Some member with (i.e Cystic Fibrosis) prevent them from being able to endure a lag-time till a pharmacy can be located that has brand on hand. Also, transport issues come into play as well.
- Flu Season Tamiflu treatment should begin within 48-hours. During a brand name shortage, we allowed generics to pay. Again we were audited for non compliance of the formulary.
- **FL Generics Law** Many pharmacist are hesitant to dispense a BRAND when a generic exists based on FL generics law. If prescriber did not indicate DAW OR BRAND NAME ONLY.
- **Burden of Brand Name** Requiring Brand prescriptions can cause hard ship on Independent Pharmacies increasing their inventory



Questions or Comments?







Michael Jackson, B.Pharm, C.Ph. Executive Vice President and CEO, Florida Pharmacy Association

Michael has been a licensed pharmacist in both Florida and Alabama for over 40 years. His practice experience includes independent and chain pharmacy as well as hospital and veterinary hospital pharmacy. He has management experience including responsibilities of over 58 pharmacies in the states of Florida, Alabama and Mississippi. He has also served on various state councils and boards including the Drug Utilization Review Board (Florida Medicaid), Collaborative Drug Therapy Management Task Force, Florida Health Insurance Advisory Board, Florida Commission on Excellence in Health Care (2001), ePrescribe Florida Advisory Council, Florida Health Information Exchange Coordinating Committee, Florida Governor's Health Information Infrastructure Advisory Board, the Florida Agency for Health Administration Electronic Prescribing Advisory Panel, and the Florida Department of Environmental Protection-Biomedical Pharmacy Technical Advisory Committee.

Michael also served 3 years in academia coordinating the professional experiential learning program at Florida A&M University as well as teaching and pharmacy practice responsibilities at Tuskegee University's College of Veterinary Medicine. He has published over 400 articles and newsletters and has been quoted in several national publications. Michael is currently the Executive Vice President and Chief Executive Officer of the Florida Pharmacy Association and is past president of the National Alliance of State Pharmacy Associations.



Unifying and strengthening the voice of pharmacy while advancing pharmacy practice through education, advocacy collaboration, and relationships

November 4, 2019

Senator Doug Broxson, Chair Senate Banking and Insurance Committee 404 S. Monroe Street Tallahassee, FL 32399-1100

Re: Pharmacy Benefit Manager Impact on the Pharmacies and Patients

Dear Senator Broxson,

Thank you for allowing us to provide comment to the Banking and Insurance Committee on Pharmacy Benefit Manager (PBM) issues. Our membership includes community, hospital, consultant and long term care pharmacists as well as pharmacists in government service, academia and a variety of other practice settings. Our organization has as our membership a number of professional pharmacy students, technicians as well as individuals who do not have a formal pharmacy training background but have an interest in the practice and business of pharmacy. There are also over 18 regional and local pharmacy organizations that are affiliated with the Florida Pharmacy Association. Issues related to revisions of public policy are routinely shared with these organizations.

The Florida legislature will be facing a wide variety of health policy proposals across interest groups. In many cases the most significant challenges for Florida will be those related to cost and quality of health care. This by far represents one of the biggest tasks that the Senate Banking and Insurance Committee must deal with when running a state the size of ours. Evidence shows through various studies that pharmacists help to lower health care costs as well as improve the proper utilization of prescription drugs and
devices. Our services in our state's licensed pharmacies go far beyond the processing of prescriptions or medication orders. We are charged with the responsibility of ensuring that the drug product selected is appropriate for each patient. Some medications that are given together may cause undesirable effects. When we provide medications to patients we search for problems related to drugs interacting with each other, diseases and drugs that should not be combined or problems related to taking drugs with certain foods.

There is a pharmacy within 5 miles of every household in America. Nearly every citizen of this state will visit a pharmacy each month. Florida licensed pharmacists are available for health care consultations evenings, nights, weekends and holidays. Most do not even require an appointment. We are this state's most accessible health care professional working hard to solve the health needs of Florida.

Changes in Florida laws approved by the legislature and signed by previous governors allow pharmacists to immunize adult patients for influenza, pneumonia, shingles as well as a host of other vaccine preventable diseases recommended by the Center for Disease Control and Prevention. Well over millions of doses of flu vaccines have been administered to patients who probably would not have received a flu shot otherwise.

Having shared the above with the Committee it is important to note that our industry is also besieged by an unregulated third party middle man that has created negative disruption within the pharmacy small business community and taken away consumer choice. That entity is called a pharmacy benefit manager (PBM). Florida laws define a pharmacy benefit manager as a person or entity doing business in this state which contracts to administer prescription drug benefits on behalf of a health insurer or health maintenance organization to residents of this state. Nearly every prescription provided to consumers in this state must come through a pharmacy benefit manager or PBM. There is not much known about this industry which also means there is a lot of confidential information related to prescription drug costs that the public does not have access to. Just recently states like Ohio have been looking into PBM practices and found over \$220 million in overbilling of Medicaid by pharmacy benefit managers. That excess billing costs taxpayer dollars that could have been used for other essential state health care services. With Florida being a much larger state the scale of this problem could be greatly magnified. Here in Florida the legislature began looking at the PBM marketplace when it was discovered that pharmacy providers were being prohibited from sharing information with patients about lower cost alternatives for their prescription medications. House bill 351 was adopted in 2018 to prohibit plan contracts with PBMs from interfering with a pharmacist's obligation to disclose lower cost options. Also over the years it was necessary to advocate for changes in Florida laws to create fair auditing standards. Unfair auditing procedures that were not clear to pharmacies resulted in massive paybacks to PBMs. In many of these cases not only was the pharmacy's fees taken away but also the cost of the prescription drug that the pharmacist legally dispensed to a patient for a drug prescribed by a physician and paid for by the pharmacy.

Pharmacies today are also not clear on how pricing is being determined and what they are being paid for their services. There is no other health care provider that we are aware of which operates in an unknown reimbursement space like this. Certain prescription drugs are placed into what is known as a maximum allowable cost (MAC) price list that is supposed to be updated regularly however there is no way to validate that is being done and no method in place for a pharmacy to seek relief when there is belief that a MAC list is noncompliant. Pharmacies are being told that the method to determine a MAC price is confidential and cannot be disclosed.

Perhaps it may be easy under some business practices to simply elect to disagree with the terms and conditions of a managed care or PBM contract but in reality the options are to either accept or not accept a contract in its entirety. This can be devastating for pharmacy businesses in areas dominated by a single PBM.

For the past several years we believe that pharmacy providers have been subsidizing the costs of prescription drug health care. It has created an unhealthy market place for consumers and to some extent, we believe that eventually it could create some access and cost issues for consumers particularly in medically underserved areas of Florida if a pharmacy continues to provide services below their costs.

Our members are working hard to provide medication management services for the patients in their communities. These pharmacies have cared for these patients for many years and have managed the health of not only those patients but their family members as well. Florida based pharmacy businesses are locally owned and operated and pay taxes and fees for the privilege of serving their communities. Taxes and fees paid by

Florida based pharmacy businesses and Florida licensed pharmacy personnel are used to fund the very health care support programs used to treat the indigent and underserved. Many of these Florida based businesses are supporting their communities through sponsorship of local charities and events and are contributing to the creation of jobs and the local economy. They have a corporate footprint on Florida soil but in some cases they may be shut out of networks and banned from helping those who cannot help themselves. Pharmacies that can provide the credentials show the quality of care and are willing to accept the terms and conditions of a managed care contract should not simply be brushed off as an undesired provider of pharmacy services.

On behalf of the many thousands of pharmacy stakeholders I want to thank you for allowing us to provide these comments and I am available to answer any questions that you may have.

With kindest regards,

Michael a. Julian

Michael A. Jackson, BPharm EVP & CEO



610 North Adams Street, Tallahassee, Florida 32301 www.floridapharmacy.org

Steven McCall, R.Ph., M.B.A. Vice President of Network Services, CVS Caremark

Steven McCall is the Vice President of Network Services for CVS Caremark. His responsibilities include overseeing the audit and pharmacy credentialing functions.

Steve started as a pharmacy technician over 30 years ago in a small independent pharmacy in Washington State. Following graduation, he took a job as a retail pharmacist servicing patients in Central Florida. He later moved on to a closed door pharmacy in Arizona servicing LTC, Assisted Living and Hospice populations. Steve attended business school and worked as the Director of Pharmacy for a small hospital corporation with financial responsibility for four locations. He later worked for 4 years as a clinical team leader and dispensing pharmacist with a national home infusion/specialty pharmacy. Steve has been in the field of pharmacy since 1987 and licensed as a pharmacist for 24 years.

Steve has a degree in Pharmacy from Washington State University and a MBA degree with a concentration in Services Marketing and Management from Arizona State University. He is a member of the National Healthcare Anti-Fraud Association (NHCAA) and the National Association of Drug Diversion Investigators (NADDI).

Pharmacy Audits

November 5, 2019

Steve McCall, R.Ph., MBA Vice President, Network Services



©2014 Caremark. All rights reserved. This presentation contains confidential and proprietary information of CVS/caremark and cannot be reproduced, distributed or printed without written permission from CVS/caremark.

Integrated Audit Solutions to Help Mitigate Fraud, Waste and Abuse



- Multiple levels of review to help curb waste and educate pharmacies on proper claims submission
- Continuous monitoring identifies suspicious claims patterns
- Inappropriate activities addressed through plan edit enhancements or law enforcement

CVS/caremark[®]

In 2018, Pharmacy Audits Educated more than 70% of Network Pharmacies

Daily Reviews - How they work



Daily Claims Review - Benefits

- Daily Reviews are designed to validate claims submissions with minimal impact
- Designed to be invisible
 - Pharmacy has a chance to correct claims errors before they are impacted financially
 - Members are not aware that pharmacy made an error in the billing avoiding questions as to pharmacy quality and harming the pharmacistpatient relationship
 - Plan sponsors do not have to wait for financials to be corrected without an onsite audit
- Daily Reviews audits key off of red flags that could lead to an onsite or investigational audit thus reducing likelihood of further audit efforts
- Great educational opportunity for pharmacies to improve processes



Onsite Audits - How they work

Pharmacy Submits claim for medication to Caremark through adjudication

All claims are pulled for a pharmacy and compared against rules versus the pharmacy's peer group creating risk score

Onsite auditor pulls claims profile using risk score. Claims are selected for review of the submission versus the hard copy

Auditor performs an onsite visit to audit claims and educate pharmacy on proper submission techniques



Onsite Audits

CVS Caremark plan sponsors want to insure that a sample of pharmacies are visited in person to compare hard copy prescription with the information submitted by the pharmacy.

These audits are designed to be approximately 60 - 90 minutes and not disrupt patient care. They have a large educational component so any discrepancies found can be understood to prevent re-occurrence and charge backs.



Proactive Approach to Education of Network Pharmacies

Audit Tips distributed to Pharmacies, Chains, and PSAO's to inform pharmacists of common errors seen in the marketplace and trends

Provider Manual lists medications with unusual submission and details regarding the requirements of claim submission and expectations related to audit

Education and exit interview provided at end of each onsite and investigative audit to answer all pharmacy staff questions related to accurate claims processing and review discrepancies noted in audit

Meetings with chain and PSAO affiliations to address audit findings and provide tips

Continuing Education presentations to pharmacists and technicians in network pharmacies on accurate claim transmission and audit preparation



Dr. Scott McClelland , Pharm.D., R.Ph, CHIE Vice President, Commercial and Specialty Pharmacy, BCBS

Dr. Scott McClelland is Florida Blue's Vice President of Commercial and Specialty Pharmacy. In his role, he is responsible for leading the pharmacy unit as well as the oversight and development of the clinical and operational strategy for the traditional, specialty and medical pharmacy areas, to ensure members have access to clinically sound and affordable pharmacy benefits and programs.

Prior to joining Florida Blue in 2006, Dr. McClelland held a leadership position within the HCA Hospital System as the Manager of Pharmacy Operations. He has over 20 years of experience as a clinical pharmacist specializing in critical care hospital based medicine and pharmacy benefit management.

Throughout his career, Dr. McClelland has been active in community and professional organizations. He is a member of the Academy of Managed Care Pharmacy (AMCP); America's Health Insurance Plans (AHIP); American Society of Health-System Pharmacist (ASHP); and has served as adjunct professor to several university systems.

Dr. McClelland received his Bachelor of Science and Doctorate of Pharmacy degree from the University of Georgia. In addition, he completed an ASHP Pharmacy Practice Residency, received his Health Information Certification from the Blue Cross Blue Shield Association and was certified as a health insurance executive through America's Health Insurance Plans (AHIP) leadership program.

LuGina Mendez-Harper, PharmD, RPh State Government Affairs Principal, Prime Therapeutics

LuGina Mendez-Harper is a State Government Affairs Principal with Prime Therapeutics. She has been a pharmacist for over 20 years and has worked in a variety of clinical, administrative, regulatory, and legislative settings. She earned her Bachelor of Science degree in Pharmacy at the University of New Mexico. She obtained her Doctor of Pharmacy degree Magna Cum Laude from the University of Kansas. She also completed a Post-Doctoral Fellowship at Rutgers University and Bristol-Myers Squibb in Pharmacy Education and Drug Information.

Dr. Mendez-Harper has held positions in various aspects of pharmacy including the national association of pharmacists, community pharmacy, mail service pharmacy, specialty pharmacy, Indian Health pharmacy, and managed care pharmacy. Dr. Mendez-Harper served on the New Mexico Board of Pharmacy for 6 years and serves in various district and national state board of pharmacy association leadership roles. She is currently a member of the Accreditation Council for Pharmacy Education (ACPE) Board of Directors and Board liaison to the ACPE International Commission. She was appointed to the ACPE Board of Directors as the National Association of Boards of Pharmacy. ACPE assures and advances excellence in pharmacy education both with professional pharmacy degree programs and pharmacy continuing education providers. In her current role as State Government Affairs Principal with Prime Therapeutics, Dr. Mendez-Harper covers legislative and regulatory activities impacting all areas of pharmacy in 9 states including Florida.



The Role of Pharmacy Benefit Managers in the Private Insurance Market

Florida Senate Banking and Insurance Committee Meeting

November 5, 2019

LuGina Mendez-Harper, PharmD, RPh Government Affairs Principal



6810 © Prime Therapeutics | Confidential

What is a Pharmacy Benefit Manager (PBM)?

Pharmacy Benefits Manager - PBM

 A health care company that contracts with plan sponsors (insurers, self-funded employers, unions, and government programs) to administer the prescription drug portion of the health care benefit

BlueCross BlueShield		
Subscriber Name: JOHN DOE Identification Number: XOF123456789		
Group Number: 123456 Coverage Date: 09/01/08	Office Copay Emergency Copay	\$20 \$100
	RX Generic Copay RX Brand Copay	\$25 \$50/\$100
SINGLE	RxBIN: 011550 RxPCN: ILDR	129908961538963
	PPO	PPO R

Who do Pharmacy Benefit Managers (PBMs) Work For?



6810 © Prime Therapeutics | Confidential

The Value of Pharmacy Benefit Managers (PBMs)



PBMs aggregate the buying clout of millions of enrollees, enabling plan sponsors and individuals to obtain lower prices for their prescription drugs.

6810 © Prime Therapeutics | Confidential

Pharmacy Benefit Manager (PBM) Core Services



Claims Processing



Formulary Management



Drug Utilization Review



Disease Management and Adherence Initiatives



Price, Discount and Rebate Negotiations with Pharmaceutical Manufacturers and Pharmacies



Pharmacy Networks



Mail-service Pharmacy



Specialty Pharmacy

6810 © Prime Therapeutics | Confidential

The Plan Sponsor Request For Proposal (RFP) Process



6810 © Prime Therapeutics | Confidential

The Drug Supply Chain



Pharmacy Benefit Managers (PBMs) in the Drug Supply Chain

PBMs Generate Savings for Plan Sponsors by Negotiating Discounts with Pharmacies and Rebates from Brand Name Drug Manufacturers



6810 © Prime Therapeutics | Confidential

Pharmacy Benefit Managers (PBMs) and Pharmacies



- Pharmacies may contract directly with PBMs
- Over 80% of independent pharmacies delegate contracting with a PBM to a Pharmacy Services Administrative Organization (PSAO)
 - PSAOs aggregate buying power of independent pharmacies to negotiate contracts with PBMs and other third-parties
 - Pharmacies may also delegate other services to PSAOs such as MAC appeals, drug purchasing, payment, and audits
- PBMs have no insight into private contracting terms between PSAOs and pharmacies

Drug Wholesalers Own 3 Largest PSAOs

Pharmacy Franchise and Marketing Programs, 2016 Good Neighbor Medicine CARE Sav-Mor Health Benzer PROGRAM Shoppe/Medicap Drugstores Pharmacy Pharmacy Mart Pharmacies Cardinal Health Ownership McKesson AmerisourceBergen Independent Independent Independent # of Participating 4,800 2,800 515 82 65 71 Pharmacies 2016 Prescription \$10.2 \$7.3 \$1.9 \$.07 \$.02 \$.03 Revenues (billions)

McKesson's PSAO – HealthMart Represents More Pharmacies Than Wal-Mart

Source: Drug Channels Institute estimates; company reports. Drug Store News.

Pharmacy Benefit Managers, Manufacturers, and Plan Sponsors

- Only if a brand name drug has clinically equivalent competitors can a PBM negotiate rebates with manufacturers in exchange for preferred formulary placement
- Pharmacy Benefit Managers pass rebates to the plan sponsor who uses it to lower the cost of the benefit (i.e., premiums)
 - The plan sponsor dictates exactly how the rebate is shared
 - The plan sponsor retains full audit rights in their PBM contracts ensuring transparency



Pharmacy Benefit Managers (PBMs) Delivering Value

PBMs save plan sponsors and consumers an average of 35% compared to expenditures made without pharmacy benefit management



Head to Head Competition Reduced the Cost of an Average Hepatitis C Drug by More Than 40%

Source: Visante, prepared for PCMA. February 2016.

There Is No Correlation Between Rebates and Drug Prices

- Drug manufacturers control, set, and change the price of their drugs
- Plan sponsors and Pharmacy Benefit Managers (PBMs) have no control over the price a manufacturer sets for a drug but PBMs have some tools to drive down drug costs
- Until other drugs are approved for the same disease/condition, manufacturers have little incentive to reduce their prices
- Analysis of top brand name drugs by total spending between 2012 and 2017 showed the list price of drugs did <u>not</u> correlate with rebates



13

Source: PCMA and Visante analysis of data from CMS and SSR Health, 2018.

The Role of Pharmacy Benefit Managers (PBM's) in the Health Care System

- Plan sponsors are not required to use a PBM, most do because PBMs drive adherence, hold down costs, and increase quality
 - PBMs help save plans 40-50% over unmanaged benefits¹
- PBMs work for plan sponsors to exert downward pressure on prescription drug costs
 - PBMs are expected to save \$654B nationally in 10 years²
- Plan sponsors always have the final say when creating drug benefits
 - There is no one-size-fits-all model each plan sponsor has unique needs

1. Visante, Return on Investment on PBM Services, Nov. 2016.

2 Visante, Generating Savings for Plan Sponsors, Feb. 2016, available at: - https://www.pcmanet.org/wp-content/uploads/2016/08/visante-pbm-

savings-feb-2016.pdf



Thank you

LuGina Mendez-Harper, PharmD, RPh Prime Therapeutics Government Affairs Principal Imendezharper@primetherapeutics.com Cellular Telephone: 505-206-1089

THE FLORIDA SENATE

APPEARANCE RECORD

$\left(1\right) 5 2019$ (Deliver BOTH c	opies of this form to the Senator of	or Senate Professional Sta	
Meeting Date			Bill Number (if applicable)
Topic PRESENTATIONS ON THE	NOLY OF PHARMACY A	STWEFT MANAGE	Amendment Barcode (if applicable)
Name MICHAR JACKSON			
Job Title <u><u>tvp</u> & CED</u>			
Address 610 N. ADAMS	JT		Phone (850) 222 - 2400
Street			N N
TAUANANEE	FL	32301	Email MJACKSON @ PHARMVIEW. LOM
City	State	Zip	
Speaking: For Against	Information		Speaking: In Support Against
Representing FLORIDA	PHANMACY ASSO	CIATION	
Appearing at request of Chair:	X Yes X No	Lobbyist regist	tered with Legislature: 🛛 Yes 🗌 No
While it is a Senate tradition to encoura meeting. Those who do speak may be	age publić testimony, time	e may not permit all	I persons wishing to speak to be heard at this

This form is part of the public record for this meeting.

THE FLOI	RIDA SENATE
Deliver BOTH copies of this form to the Senator Meeting Date	ICE RECORD or Senate Professional Staff conducting the meeting)
Topic <u>PBM</u> Workshop	Bill Number (if applicable)
Name Barney Bishop II	Amendment Barcode (if applicable)
Job Title Chief Executive Office - Bar	ney Bishop Consulting
Address 2215 Thomasville Road	Phone 850,510,9922 Barneye
Thill apassee FL City State	<u>32308</u> Email <u>Barney Bishop.com</u>
Speaking: For Against Information	Waive Speaking: In Support Against (The Chair will read this information into the record.)
Representing SPAR-Small Business Ph	armacies Aligned for Reform
Appearing at request of Chair: Yes No	Lobbyist registered with Legislature:
While it is a Senate tradition to encourage public testimony, time meeting. Those who do speak may be asked to limit their remark.	may not permit all persons wishing to speak to be heard at this s so that as many persons as possible can be heard.

THE FLORIDA SENATE	
APPEARANCE RECO	RD
(Deliver BOTH copies of this form to the Senator or Senate Professional S	taff conducting the meeting)
Meeting Date	Bill Number (if englise (1))
Topic PRM	Bill Number (if applicable)
	Amendment Barcode (if applicable)
Name Scott Mechelland	
Job Title VP Pharman Programs Florida Blue.	
Address 4500 Decrivood Compus	Phone 904-905-1133
City State Zip	Email Scott. Mcclellund @bebsfl. un
Speaking: For Against Information PANE) Waive Sp	peaking: In Support Against r will read this information into the record.)
Representing Florida Blue	
Appearing at request of Chair: Ves No Lobbyist register	ered with Legislature:
While it is a Senate tradition to encourage public testimony, time may not permit all µ meeting. Those who do speak may be asked to limit their remarks so that as many p	

1

1

THE FLORIDA S	ENATE
NOV. 5, 2019 (Deliver BOTH copies of this form to the Senator or Senar Meeting Date	te Professional Staff conducting the meeting)
Topic <u>PBM Work shop</u> Name Ipm Brownli	Bill Number (if applicable)
Name Tom Brownly	Amendment Barcode (if applicable)
Job Title Sinier Director	
Address 235 & Y2 ^{b1} St Street	Phone $617 - 958 - 9983$
NW Yok M 100 City State Speaking: For Against Mnformation	
Representing PFizer	an entration into the record.)
Appearing at request of Chair: Yes No Lobb	yist registered with Legislature: Yes No
While it is a Senate tradition to encourage public testimony, time may no meeting. Those who do speak may be asked to limit their remarks so the This form is an () for the senar	

r

	ORIDA SENATE
(Deliver BOTH copies of this form to the Senat Meeting Date	NCE RECORD for or Senate Professional Staff conducting the meeting)
	Bill Number (if applicable)
Topic PHARMACY BEJEFIT MANAGE	RS
Name TRICA FITZSIMMONS	Amendment Barcode (if applicable)
Job Title Director, Public Polic	4
Address One Health Plaza	Phone 609-955-2909
East Hanover NJ City State	07920 Email tricia fitzsimmonse
Speaking: For Against Information	Waive Speaking: In Support Against (The Chair will read this information into the record.)
Representing Novartis	
Appearing at request of Chair: Yes No While it is a Senate tradition to encourage public testimony, time meeting. Those who do speak may be asked to limit their remain	Lobbyist registered with Legislature: Yes No e may not permit all persons wishing to speak to be heard at this rks so that as many persons as possible can be heard
This form is part of the public record for this meeting.	

THE FLO	RIDA SENATE
//-6-(9 (Deliver BOTH copies of this form to the Senator	NCE RECORD r or Senate Professional Staff conducting the meeting)
Meeting Date Topic Presentation on the Role of Pharmocy ken	Bill Number (if applicable)
Name Share Abbott	Insurance Markel
Job Title Pharmacist / Pharmacy Co-Owner	
Address 13.37 US Mwg 90 West	Phone 850 - 892- 6898
DeFuniak Springs, FL 32433 City State Speaking: For Against Information	Zip Waive Speaking: In Support Against (The Chair will read this information into the record.)
Representing	
Appearing at request of Chair: Yes No	Lobbyist registered with Legislature:
While it is a Senate tradition to encourage public testimony, time meeting. Those who do speak may be asked to limit their remark.	may not permit all persons wishing to speak to be heard at this is so that as many persons as possible can be heard.

The Florida Senate	
APPEARANCE RECO	RD
(Deliver BOTH copies of this form to the Senator or Senate Professional St	
Meeting Date	Bill Number (if applicable)
Topic Role of PBM in Insurance	Amendment Barcode (if applicable)
Name Jacqueline Jacobi	
Job Title Rigional Director of Pharmacy for Molina	Healthcare
Address 1550 Othsco Valley RA	Phone 607-745-649
Marricha My 13/16 City State Zip	Email Jacobi 6913 @twc. com
Speaking: For Against Information Waive Sp	eaking: In Support Against will read this information into the record.)
Representing Molina Heathcare	
Appearing at request of Chair: Yes No	red with Legislature: Yes No
While it is a Senate tradition to encourage public testimony, time may not permit all preeting. Those who do speak may be asked to limit their remarks so that as many p	Persons wishing to appak to be be and at u

THE FLOA	RIDA SENATE
	ICE RECORD or Senate Professional Staff conducting the meeting)
Meeting Date	Bill Number (if applicable)
Topic	Amendment Barcode (if applicable)
Name Steve M. Call R.	Ph_
Job Title VP, Notwork Service	<u>S</u>
Address 950 E Shea Blac	Phone 480-614-7326
Scottsdale AZ	85213 Email
City State	Zip
Speaking: For Against Information	Waive Speaking: In Support Against (The Chair will read this information into the record.)
Representing CVS Health	
Appearing at request of Chair: Yes No	Lobbyist registered with Legislature: Yes XNo
While it is a Senate tradition to encourage public testimony, time meeting. Those who do speak may be asked to limit their remar	e may not permit all persons wishing to speak to be heard at this ks so that as many persons as possible can be heard.

This form is part of the public record for this meeting.	S-001 (10/14/14)

THE FLORIDA SENATE	
APPEARANCE RECORD	
$\frac{11-5-2019}{Meeting Date}$ (Deliver BOTH copies of this form to the Senator or Senate Professional Staff conducting the meeting	Bill Number (if applicable)
Topic Prescription Drug Panel Amer	ndment Barcode (if applicable)
Name UGina Mondez Harper	
Job Title Govt Affairs Rineipal	
Address Phone <u>505</u>	-206-1081
Street Email Marget City State Zip Speaking: For Against Against Information Waive Speaking: In State In State In State	Dezlfar per Q West Levapentics, Support Against Com mation into the record.)
Representing	
Appearing at request of Chair: 🗶 Yes 🗌 No 🛛 Lobbyist registered with Legisla	iture: Yes No
While it is a Senate tradition to encourage public testimony, time may not permit all persons wishing to meeting. Those who do speak may be asked to limit their remarks so that as many persons as possible	•
This form is part of the public record for this meeting.	S-001 (10/14/14)

- ----

CourtSmart Tag Report

Room: KN 4 Caption: S	12 enate Banking and Insura	Case No.: nce Committee	Type: Judge:
Started: 11	/5/2019 2:03:23 PM		
	/5/2019 3:59:13 PM	Length: 01:55:51	
2:03:22 PM	Meeting called to orde	r Roll call	
2:03:33 PM	Quorum is present		
2:03:52 PM		d recognizes Senator Rousson	
2:04:25 PM		ains the purpose of the panel ar	nd discussion today
2:07:03 PM	Senator Rousson intro		
2:08:04 PM	Chair Broxson gives d	irection on question and answer	time
2:08:38 PM		cist/ Pharmacy co-Owner of Def	uniak Springs presents
2:18:46 PM	Chair Broxson with qu	estion to Mr. Abbott	
2:19:13 PM	Mr. Abbott answers		
2:20:31 PM	Chair Broxson moves		
2:20:50 PM		er, Government Affairs Principal	
2:21:46 PM	Ms. Mendez Harper p	esents	
2:29:23 PM 2:29:36 PM	Member questions	question for LuGina Mendez Ha	arpor
2:30:01 PM	Ms. Harper responds		
2:30:20 PM		Steve McCall R_Ph_VP Netwo	ork Services of Scottsdale AZ for CVS He
2:31:47 PM	Steve McCall presents		
2:36:20 PM		mment about presentation	
2:37:36 PM	Mr. McCall responds	·	
2:37:45 PM	Chair - with question		
2:37:52 PM	Mr. Steve McCall		
2:37:59 PM	Mr. Steve McCall		
2:37:59 PM	Mr. Steve McCall		
2:38:06 PM	Chair responds		
2:38:14 PM	Steve McCall		
2:38:24 PM	Senator Gruters with o		
2:38:36 PM 2:39:17 PM	Steve McCall respond Senator Thurston with		
2:39:44 PM	Senator Thurston	question on addit	
2:40:18 PM	Steve McCall answers		
2:40:25 PM		to next speaker Tom Brownlie	
2:40:59 PM		Director of Pfizer from New York	NY
2:42:18 PM	Chair Broxson with qu	estion on price	
2:43:20 PM	Mr. Brownlie with answ	ver	
2:46:47 PM	Chair Broxson with co		
2:48:07 PM	Senator Thurston with		
2:48:15 PM	Tom Brownlie respond		
2:49:28 PM		on to Jaqueline Jacobi	Volone Healthears of Marietta NV
2:49:49 PM 2:52:22 PM	Chair Broxson	gional Director of Pharmacy for I	Molena Healthcare of Marietta NY
2:53:31 PM		Fitzsimmons Director Public Po	licy of Novartis from East Hanover NT
2:54:33 PM	Tricia Fitzsimmons pre		
2:55:40 PM	Chair Broxson		
2:56:43 PM	Tricia Fitzsimmons an	swers question	
2:57:16 PM	Chair Broxson		
2:58:50 PM	Tricia Fitzsimmons		
2:58:58 PM	Senator Rousson with		
2:59:25 PM	Tricia Fitzsimmons res		
2:59:42 PM		question about list price	
2:59:55 PM	Tricia answers	stion about DPM	
3:00:13 PM 3:00:29 PM	Senator Thurston que Tricia Fitzsimmons res		
5.00.23 I WI			

3:00:57 PM	Chair Broxson moves on to Scott McClelland VP Pharmacy Programs Florida Blue Jacksonville FL
3:01:55 PM	Scott McClelland Vice President Pharmacy Programs Florida Blue of Jacksonville FL
3:05:03 PM	Chair Broxson with question on PBM discounts
3:06:04 PM	Scott McClelland answers
3:06:13 PM	Chair Broxson
3:06:15 PM	Scott McClellan
3:06:54 PM	Senator Rousson
3:07:15 PM	Michael Jackson is next speaker
3:07:43 PM	Michael Jackson Executive Vice President & CEO Florida Pharmacy Association
3:11:41 PM 3:12:46 PM	Chair Broxson with question Michael Jackson responds
3:12:59 PM	Chair Broxson on secrecy
3:13:11 PM	Michael Jackson responds
3:15:03 PM	Chair Broxson opens for comments
3:16:11 PM	Senator Thurston for Mr. Jackson on DIR fee
3:16:30 PM	Mr. Jackson responds
3:18:16 PM	Chair Broxson
3:19:17 PM	Senator Thurston follow up question
3:19:33 PM 3:19:36 PM	Chair Broxson
3:20:52 PM	Michael Jackson responds Chair Broxson questions Senator Lee
3:21:12 PM	Senator Lee with answer
3:23:48 PM	Chair Broxson follow up question to Tricia Fitzsimmons
3:24:50 PM	Tricia Fitzsimmons responds
3:25:15 PM	Chair Broxson follow up to Tricia Fitzsimmons
3:25:51 PM	Tricia Fitzsimmons with suggestion
3:26:44 PM	Chair Broxson recognizes Senator Thurston
3:27:00 PM	Senator Thurston with question on manufacture standpoint
3:27:40 PM	Tricia Fitzsimmons responds
3:29:33 PM 3:30:13 PM	Senator Taddeo with question Tom Brownlie responds
3:32:02 PM	Mr. Abbott to comment on discussion
3:33:49 PM	Steve McCall comments on the same issue
3:35:20 PM	Chair Broxson with comment on the issue
3:35:34 PM	Mr. McCall comments
3:35:45 PM	Chair Broxson
3:36:35 PM	Senator Gruters with question
3:37:05 PM	LuGina Mendez Harper answers the question on rebates and PBMs
3:37:58 PM	Chair Broxson with comment LuGina Mendez Harper responds
3:39:21 PM 3:39:54 PM	Chair Broxson follow up
3:40:08 PM	LuGina Mendez Harper responds
3:41:28 PM	Chair Broxson
3:41:37 PM	Jacqueline Jacobi
3:42:04 PM	Chair Broxson to Ms. Fitzsimmons -about rebates
3:42:36 PM	Ms. Fitzsimmons responds on negotiation
3:44:24 PM	Senator Gruters with follow up question
3:44:39 PM	Tricia Fitzsimmons
3:45:07 PM 3:46:49 PM	Senator Lee is recognized Jaqueline Jacobi - responds to Senator Lee question
3:49:22 PM	Tom Brownlie responds on same question
3:50:59 PM	Chair Broxson with question
3:51:26 PM	Tricia Fitzsimmons to answer on value and delivery
3:53:02 PM	Chair Broxson
3:53:10 PM	Question on insulin cost
3:53:25 PM	Tom Brownlie responds
3:54:53 PM	Chair Broxson opens for members to question
3:55:10 PM	Senator Lee with question
3:56:04 PM 3:56:42 PM	Shane Abbott answers Senator Lee
3:56:42 PM	Senator Lee Shane Abbott
3:57:27 PM	Senator Lee

3:57:31 PM

- 3:58:01 PM
- Steve McCall Chair Broxson wraps up Senator Perry moves we adjourn. The meeting is adjourned 3:58:30 PM
- 3:58:55 PM